Marino Stram & Associates’s Teva Pharmaceuticals TEVA Stock Holding History

Marino Stram & Associates’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-621	Closed	-$10K	–	503
2019 Q1	$10K	Hold	621	–	–	0.01%	304
2018 Q4	$10K	Hold	621	–	–	0.01%	279
2018 Q3	$13K	Hold	621	–	–	0.01%	281
2018 Q2	$15K	Hold	621	–	–	0.01%	269
2018 Q1	$11K	Hold	621	–	–	0.01%	305
2017 Q4	$12K	Buy	+621	New	+$9.34K	0.01%	296

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Marino Stram & Associates's TEVA Position: Q2 2019 in Review

Marino Stram & Associates sold out of Teva Pharmaceuticals (TEVA) in Q2 2019, closing a stake of 621 shares — an estimated $10K sold.

Marino Stram & Associates first reported a position in TEVA in Q4 2017 and held it in 6 quarters. The position peaked at $15K in Q2 2018. 452 funds tracked by Wall St. Rank hold TEVA as of Q2 2019.

Marino Stram & Associates reported no remaining Teva Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Marino Stram & Associates sold 621 Teva Pharmaceuticals shares in Q2 2019, an estimated $10K.
Marino Stram & Associates first reported a position in Teva Pharmaceuticals in Q4 2017 and held it in 6 quarters.
Marino Stram & Associates's Teva Pharmaceuticals position peaked at $15K in Q2 2018.
452 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2019.

Based on Marino Stram & Associates's 13F filing for Q2 2019, filed 19 Jul 2019.